Search clinical trials for: TmCD19-IL18

Total 554 results

University of Pennsylvania
Kite, A Gilead Company

Recruiting

TmCD19-IL18 in CD19+ Cancers

Non Hodgkin Lymphoma

United States
Hospices Civils de Lyon

Not yet recruiting

Effect of Burosumab on the Inflammatory Profile of Patients With X-linked Hypophosphatemic Rickets FLAM-XLH (FLAM-XLH)

X-Linked Hypophosphatemic Rickets
Kai Lin Xu; Jun Nian Zheng
First Affiliated Hospital of Zhejiang University; Nantong University; Affiliated... and other collaborators

Recruiting

Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

China
University of Pennsylvania

Recruiting

huCART19-IL18 in NHL/CLL Patients

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-hodgkin Lymphoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid Leukemia

United States
INSYS Therapeutics Inc
Pediatric Brain Tumor Consortium (PBTC), St. Jude Children's Research Hospital

Withdrawn

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Recurrent Malignant Glioma

United States
National Institute of Neurological Disorders and...

Terminated

An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma

Glioma | Brain Neoplasm

United States
Ajman University

Completed

Estimation of Sialic Acid and IL10 Levels in Stage 1 and 2 Periodontitis Patients

Periodontal Disease

India
Bristol-Myers Squibb

No longer available

Expanded Access for Anti-IL8
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Suzhou University

Unknown

The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | B Acute Lymphoblastic Leukemia

China
University Hospital, Antwerp
Kom Op Tegen Kanker; Stichting tegen Kanker

Recruiting

First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients (IL15-TransDC)

Esophageal Cancer | Ovarian Cancer | Pancreas Cancer | Liver Cancer

Belgium
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

Glioblastoma | Ependymoma | Medulloblastoma | Recurrent Metastatic Malignant Neoplasm in the Leptomeninges

United States
INSYS Therapeutics Inc

Completed

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

Glioblastoma Multiforme | Malignant Glioma | Anaplastic Astrocytoma | Mixed Oligoastrocytoma

United States
INSYS Therapeutics Inc

Completed

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

Glioblastoma Multiforme | Malignant Glioma | Anaplastic Astrocytoma | Mixed Oligoastrocytoma | Malignant Astrocytoma

United States
Baylor Research Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

Malignant Melanoma Stage III | Malignant Melanoma Stage IV

United States
INSYS Therapeutics Inc

Completed

Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma

Glioblastoma Multiforme | Malignant Glioma | Anaplastic Astrocytoma | Mixed Oligoastrocytoma

United States, Germany, Israel
Bristol-Myers Squibb
This trial was conducted previously by Cormorant

Completed

HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors

Solid Tumor

United States
National Cancer Institute (NCI)

Recruiting

NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Kaposi Sarcoma

United States
Shenzhen Second People's Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Unknown

EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer (EGFRCART)

Metastatic Colorectal Cancer

China
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Withdrawn

Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas

Brain and Central Nervous System Tumors
Abgenix

Completed

A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD

Pulmonary Disease, Chronic Obstructive | Bronchitis, Chronic

United States
Sonnet BioTherapeutics

Completed

Study of SON-1010 (IL12-FHAB) in Healthy Adults

Healthy Adult

Australia
National Cancer Institute (NCI)

Active, not recruiting

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

Cervical Cancer | Anal Cancer | Oropharyngeal Cancer | HPV Cancers | Vulvar, Vaginal, Penile, Rectal Cancer

United States
INSYS Therapeutics Inc

Completed

Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma

Glioblastoma Multiforme | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Mixed Oligoastrocytoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Small Bowel Cancers | Colorectal Cancers

United States
University of Colorado, Denver

Recruiting

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Acute Lymphoblastic Leukemia | Acute Lymphoid Leukemia

United States
National Cancer Institute (NCI)

Completed

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Recurrent Skin Carcinoma | Stage III Renal Cell Cancer | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Non-Small Cell Lung Carcinoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IV... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI); Food and Drug Administration (FDA)

Active, not recruiting

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III Glioma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Recurrent Glioblastoma | Refractory Glioblastoma

United States
Sohag University

Recruiting

Assessment of FOXP3 Gene Polymorphisms and Serum Interleukin 10 in Patients With ITP (FoxP3ITP)

Thrombocytopenia

Egypt
Shanghai Virogin Biotech Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients With Solid Tumors

Advanced Malignant Solid Tumor

China
Hamad Medical Corporation

Recruiting

Inflammatory Markers Dynamics in Response to Extra-corporeal Membrane Oxygenator Decannulation (ECMO)

Inflammatory Markers Changes in Response to Extra-corporeal Membrane Oxygenator Decannulation

Qatar
Boston University
Regeneron Pharmaceuticals

Completed

IL1-TRAP, Rilonacept, in Systemic Sclerosis

Systemic Sclerosis | Scleroderma | Diffuse Systemic Sclerosis | Diffuse Scleroderma

United States
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumor

China
National Cancer Institute (NCI)

Terminated

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Metastatic Pancreatic Cancer | Histologically or Cytologically Confirmed Pancreatic Cancer | Unresectable or Borderline Resectable Pancreatic Cancer

United States
Chongqing Public Health Medical Center
Zhejiang Qixin Biotech; Chongqing Sidemu Biotech

Unknown

A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19

COVID-19

China
CNBG-Virogin Biotech (Shanghai) Ltd.

Unknown

Clinical Study of VG161 in Subjects With Advanced Primary Liver Cancer

Primary Liver Cancer

China
Meridigen Biotech Co., Ltd.

Not yet recruiting

Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS)

Acute Respiratory Distress Syndrome

Taiwan
NHS Greater Glasgow and Clyde
University of Glasgow; NHS Ayrshire and Arran; Golden Jubilee National Hospital

Not yet recruiting

CharacterisatiON of carDiac funCTion in Intensive Care Unit Survivors of Sepsis. (CONDUCT-ICU)

Heart Failure | Sepsis | Septic Shock | Myocarditis

United Kingdom
Meridigen Biotech Co., Ltd.

Recruiting

Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke

Acute Ischemic Stroke

Taiwan
Meridigen Biotech Co., Ltd.

Active, not recruiting

Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Moderate

Taiwan
CNBG-Virogin Biotech (Shanghai) Ltd.

Not yet recruiting

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

Primary Hepatocellular Carcinoma
Meridigen Biotech Co., Ltd.

Recruiting

Mesenchymal Stem Cells for The Treatment of Frailty Syndrome

Frailty Syndrome

Taiwan
Sohag University

Recruiting

Plasma microRNA Levels and Some Cytokines Expression in Patients With ITP Primary Immune Thrombocytopenic Purpura (ITP) (microRNAITP)

Primary Immune Thrombocytopenia

Egypt
National Cancer Institute (NCI)

Recruiting

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Cervical Cancer | Vulvar Cancer | Colon Cancer | Anal Cancer | Vaginal Cancer | Oropharyngeal Cancer | Penile Cancer | HPV | Human Papillomavirus | Neck Cancer

United States
INSYS Therapeutics Inc

Completed

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

Glioblastoma Multiforme | Oligoastrocytoma | Anaplastic Astrocytoma

United States
Taiwan Liposome Company

Completed

The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers

COVID-19

Taiwan
PiLeJe

Completed

Efficacy of Supplementation With Probiotics as Adjuvant to Mechanical Treatment in Chronic Periodontitis

Probiotics, Periodontitis

France
University of Colorado, Denver

Active, not recruiting

Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Non Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center

Withdrawn

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Hormone Receptor Positive Breast Adenocarcinoma | Metastatic HER2 Negative Breast Adenocarcinoma

United States

Search clinical trials for: TmCD19-IL18

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations